局部注射雷株单抗治疗糖尿病视网膜病变的临床观察

目的观察局部注射雷株单抗治疗糖尿病视网膜病变的临床效果。方法分析2012年1月~2013年12月在本院眼科确诊为糖尿病视网膜病变的38例患者40只眼,接受局部注射雷株单抗,对比治疗前和治疗矫正12周后的最佳矫正视力（BCVA）、黄斑中心视网膜厚度（CRT）和黄斑总体积（TMV）的变化情况。结果治疗前BCVA平均字母数为37.11±14.27,黄斑CRT为（535.16±218.37）μm,TMV为（13.70±1.67）mm^3;治疗12周后,BCVA平均字母数为46.57±15.17,黄斑CRT为（431.27±171.26）μm,TMV为（9.24±2.07）mm^3,治疗前后比较,差异有统计学意义（P〈0.05）。所有患者在治疗期间均未见明显严重不良事件。结论局部注射雷株单抗治疗糖尿病视网膜病变,能够减小黄斑CRT和TMV,进而提高患眼视力,疗效确切。

Clinical observation of local injection of ranibizumab in the treatment of diabetic retinopathy

Objective To observe the clinical efficacy of local injection of ranibizumab in the treatment of diabetic retinopathy. Methods 38 cases of diabetic retinopathy in 40 eyes confirmed in Department of Ophthalmology of our hospital from January 2012 to December 2013 were analyzed.Local injection ranibizumab was used,and best corrected visual acuity（BCVA）,macular central retinal thickness（CRT） and macular total macular volume（TMV） before treatment and after 12 weeks treatment was compared. Results Before treatment,38 patients（40 eyes） of the BCVA was 37.11 ±14.27 average number of letters,CRT was（535.16±218.37） μm,TMV was（13.70±1.67） mm3;After 12 weeks treatment,the BCVA was 46.57±15.17 average number of letters,CRT was（431.27±171.26） μm,TMV was（9.24±2.07） mm3,the difference was significant before and after treatment（P〈0.05）.There were no adverse reaction occurred during treatment.Conclusion Local injection of ranibizumab in the treatment of diabetic retinopathy can reduce the macular CRT and TMV,can improve the visual acuities,the effect is curative.